YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
YS Biopharma, a global biopharmaceutical company, will hold an Extraordinary General Meeting on May 21, 2024, to change its name to LakeShore Biopharma and appoint new directors. Mr. Dave Chenn has been appointed as the Interim CEO with vast experience in technology, finance, and healthcare sectors.
- YS Biopharma's initiative to hold an Extraordinary General Meeting showcasing transparency and shareholder involvement.
- Appointment of Mr. Dave Chenn as the Interim Chief Executive Officer due to his extensive leadership and management experience in the technology, finance, and healthcare industries.
- Mr. Dave Chenn's background including founding successful companies and holding advisory positions in reputable organizations, demonstrating his capability to lead YS Biopharma effectively.
- Change of company name from YS Biopharma to LakeShore Biopharma may cause confusion among investors and stakeholders, affecting brand recognition and market perception.
The close of business on May 10, 2024 (Eastern Time) has been fixed as the record date of ordinary shares of the Company, par value
In addition, the board of directors of the Company (the "Board") has approved the appointment of Mr. Dave Chenn as the Interim Chief Executive Officer of the Company (the "Interim CEO"), as well as the appointment of Dr. Hui Shao, the then-current Chief Executive Officer of the Company, as the Co-Chief Executive Officer and Chief Business Officer of the Company, each effective on May 2, 2024.
Mr. Chenn has over two decades of exceptional leadership and tremendous management experience in the technology, finance, and healthcare industries, with a profound ability to drive innovation and business growth within these sectors. In 2018, he founded Oceanpine Capital ("Oceanpine"), an investment management firm which invests in innovative growth companies within the TMT and healthcare sectors in both
The Notice of the EGM and related form of proxy (collectively the "EGM Notice"), which sets forth the resolutions to be submitted to shareholder approval at the meeting, are available on the Company's website at https://investor.ysbiopharma.com/. The EGM Notice contains the details of the Zoom dial-in and instructions on how to vote for the EGM.
About YS Group
YS Group is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. YS Biopharma operates in
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements"' within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the expected growth of YS Biopharma, the development progress of all product candidates, the progress and results of all clinical trials, YS Biopharma's ability to source and retain talent, and the cash position of YS Biopharma. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of YS Biopharma's management and are not predictions of actual performance.
YS Biopharma cannot assure you the forward-looking statements in this press release will be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including those included under the heading "Risk Factors" in the Post-effective Amendment No. 2 to the Company's Registration Statement on Form F-1 filed with the SEC on January 23, 2024, and other filings with the SEC. There may be additional risks that YS Biopharma does not presently know or that YS Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of YS Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while YS Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of YS Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, YS Biopharma does not undertake any duty to update these forward-looking statements.
Investor Relations Contact
Alyssa Li
Director of Investor Relations
Email: ir@yishengbio.com
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-to-hold-extraordinary-general-meeting-on-may-21-2024-and-announces-the-appointment-of-interim-chief-executive-officer-302138588.html
SOURCE YS Biopharma Co., Ltd.